This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Apr;31(7):773-6.

doi: 10.1093/eurheartj/ehq016. Epub 2010 Feb 12.

The rise and fall of rosiglitazone

Steven E Nissen

PMID: 20154334
DOI: 10.1093/eurheartj/ehq016

Editorial

The rise and fall of rosiglitazone

Steven E Nissen. Eur Heart J. 2010 Apr.

. 2010 Apr;31(7):773-6.

doi: 10.1093/eurheartj/ehq016. Epub 2010 Feb 12.

Author

Steven E Nissen

PMID: 20154334
DOI: 10.1093/eurheartj/ehq016

No abstract available

PubMed Disclaimer

Comment in

The rise and fall of rosiglitazone: reply.
Slaoui M. Slaoui M. Eur Heart J. 2010 May;31(10):1282-4. doi: 10.1093/eurheartj/ehq118. Eur Heart J. 2010. PMID: 20499440 No abstract available.

Comment on

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.
Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD. Komajda M, et al. Eur Heart J. 2010 Apr;31(7):824-31. doi: 10.1093/eurheartj/ehp604. Epub 2010 Jan 29. Eur Heart J. 2010. PMID: 20118174 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information